<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04045301</url>
  </required_header>
  <id_info>
    <org_study_id>ITO-OMA-2018-01</org_study_id>
    <nct_id>NCT04045301</nct_id>
  </id_info>
  <brief_title>Omalizumab to Accelerate a Symptom-driven Multi-food OIT</brief_title>
  <acronym>BOOM</acronym>
  <official_title>A 15 Months, Double-Blind, Randomized Controlled Trial Comparing 20 Weeks of Two Dosages of Omalizumab to Placebo to Accelerate a Symptom-driven Oral Immunotherapy Schedule in Subjects Aged 6 to 25 Years With Multiple Food Allergies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philippe Bégin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Justine's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the dose-related efficacy of a 20-week treatment of omalizumab&#xD;
      started 8 weeks before the onset of a symptom-driven multi-food oral immunotherapy (OIT)&#xD;
      protocol at decreasing time to OIT maintenance dose. Two dosages of omalizumab will be&#xD;
      compared to placebo during an oral immunotherapy protocol for three simultaneous food&#xD;
      allergens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2b, multi-center randomized controlled trial comparing 2 doses of omalizumab&#xD;
      to placebo in subjects 6 to 25 years old with multiple food allergies undergoing a&#xD;
      symptom-driven multi-food OIT protocol.&#xD;
&#xD;
      Subjects will undergo a screening period involving a DBPCFC to a mix of three allergens which&#xD;
      will determine their eligibility and eliciting dose.&#xD;
&#xD;
      Eligible subjects will be randomized to one of 2 omalizumab dosages or placebo at a ratio of&#xD;
      2:2:1 for a total period of 20 weeks.&#xD;
&#xD;
      They will undergo initial food escalation (IFE) to determine their starting food treatment&#xD;
      mix dose for three simultaneous food allergens after a pre-treatment period of 8 weeks with&#xD;
      the study drug.&#xD;
&#xD;
      Subjects will undergo up-dosing OIT visits at the clinic every two weeks, until a maintenance&#xD;
      dose of 1500mg of protein (500mg per food) is reached (primary endpoint).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2019</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the efficacy of omalizumab at decreasing time-to-maintenance during a symptom-driven multi-food OIT protocol.</measure>
    <time_frame>Assessed up to 52 weeks after IFE</time_frame>
    <description>Time from IFE to target multi-food protein maintenance dose of 1500 mg of total food protein</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in reactivity threshold to food treatment mix after pre-treatment with study drug.</measure>
    <time_frame>Measured 8 weeks after starting investigational product</time_frame>
    <description>Measured as the amount of food allergen eliciting an objective allergic reaction on double-blinded oral food challenge or initial food escalation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average up-dosing speed while on study drug.</measure>
    <time_frame>From week 0 to week 12 post IFE</time_frame>
    <description>Average of (log of escalation %)/(days since last escalation) for all escalation visits while on study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean cumulative function of allergic adverse events attributable to food dosing throughout the trial.</measure>
    <time_frame>For one year following IFE</time_frame>
    <description>AEs will be captured using the daily dosing diary throughout the trial, including during maintenance. Any systemic reaction having occurred since the last visit will be reviewed and graded by the investigator according to the CoFAR grading system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of treatment failure</measure>
    <time_frame>At any time during the 12-month OIT phase</time_frame>
    <description>Subject which stop daily ingestion of food treatment mix, prior to achieving study maintenance dose, for a period of 14 days or more</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Food IgE-mediated Allergy</condition>
  <condition>Immunotherapy</condition>
  <condition>Omalizumab</condition>
  <condition>Physiological Effects of Drugs</condition>
  <arm_group>
    <arm_group_label>Omalizumab 16 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive omalizumab 16 mg/kg monthly doses for 12 weeks, followed by omalizumab 8 mg/kg monthly for 4 weeks and then omalizumab 4 mg/kg monthly for 4 weeks.&#xD;
Multi-food oral immunotherapy following a symptom-driven schedule will begin 8 weeks after starting study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omalizumab 8 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive omalizumab 8 mg/kg monthly doses for 12 weeks, followed by omalizumab 4 mg/kg monthly for 4 weeks and then omalizumab 2 mg/kg monthly for 4 weeks.&#xD;
Multi-food oral immunotherapy following a symptom-driven schedule will begin 8 weeks after starting study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo doses for 20 weeks. The doses will be injected every 2 or 4 weeks depending on the weight of the participant.&#xD;
Multi-food oral immunotherapy following a symptom-driven schedule will begin 8 weeks after starting study drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Omalizumab 16mg/kg</intervention_name>
    <description>Participants will receive omalizumab 16 mg/kg monthly doses for 12 weeks, followed by omalizumab 8 mg/kg monthly for 4 weeks and then omalizumab 4 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.</description>
    <arm_group_label>Omalizumab 16 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Omalizumab 8mg/kg</intervention_name>
    <description>Participants will receive omalizumab 8 mg/kg monthly doses for 12 weeks, followed by omalizumab 4 mg/kg monthly for 4 weeks and then omalizumab 2 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.</description>
    <arm_group_label>Omalizumab 8 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo for 8 weeks prior to the initiation of oral immunotherapy and 12 weeks after for a total of 20 weeks including a taper period.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Multi-food oral immunotherapy (OIT)</intervention_name>
    <description>Multi-food oral immunotherapy will be conducted to a mix of three foods. It will be started 8 weeks after study drug with an initial food escalation. Participants will undergo biweekly increase until they tolerate a maintenance dose of 1500 mg (500 mg per food) of food protein.</description>
    <arm_group_label>Omalizumab 16 mg/kg</arm_group_label>
    <arm_group_label>Omalizumab 8 mg/kg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Male or female subjects 6 to 25 years old at screening visit.&#xD;
&#xD;
          2. History of IgE-mediated allergy to at least three foods within the following list:&#xD;
             peanut, milk, egg, wheat, oat, soy, barley, rye, buckwheat, hazelnut, pecan, cashew,&#xD;
             pistachio, almond, walnut and sesame.&#xD;
&#xD;
          3. Subjects currently following a strict avoidance of these three foods.&#xD;
&#xD;
          4. Positive SPT with a largest wheal diameter ≥ 6 mm to all three foods.&#xD;
&#xD;
          5. Food-specific IgE level greater than 15 kU/L for all three foods&#xD;
&#xD;
          6. Positive DBPCFC to treatment food mix with an eliciting dose ≤ 300 mg of total food&#xD;
             protein.&#xD;
&#xD;
          7. Signed informed consent and assent.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Subjects reacting objectively to the placebo during the screening DBPCFC.&#xD;
&#xD;
          2. Severe asthma as defined by GINA 201948.&#xD;
&#xD;
          3. Active or past confirmed eosinophilic oesophagitis.&#xD;
&#xD;
          4. Subject currently under allergen immunotherapy.&#xD;
&#xD;
          5. Subject/parent with excessive anxiety unlikely to cope with study conditions as per&#xD;
             investigator's opinion.&#xD;
&#xD;
          6. Subject/parent unwillingness to comply with study requirements.&#xD;
&#xD;
          7. Subject unwillingness to ingest a daily food dose of up to 1500 mg of allergen&#xD;
             protein.&#xD;
&#xD;
          8. Inability to discontinue anti-histamine medication prior to study procedures.&#xD;
&#xD;
          9. Known allergy to omalizumab or its excipients.&#xD;
&#xD;
         10. Known allergy to components of the placebo food treatment mix that cannot be&#xD;
             substituted without interfering with the blind (e.g.: dates, banana, chocolate syrup)&#xD;
&#xD;
         11. Use of immunosuppression or immunomodulatory drug (including omalizumab) or food oral&#xD;
             immunotherapy or investigational treatment or procedure within 1 year.&#xD;
&#xD;
         12. Relative contraindication or inability to use epinephrine auto-injector.&#xD;
&#xD;
         13. Subjects receiving beta-blockers or angiotensin converting-enzyme (ACE) inhibitors.&#xD;
&#xD;
         14. Pregnancy or lactation for the duration of the study.&#xD;
&#xD;
         15. Any condition that is not compatible with the study treatment or procedures as per&#xD;
             investigator judgment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Bégin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Justine's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Hélène Lavergne, B.Sc.N.</last_name>
    <phone>(514) 345-4931</phone>
    <phone_ext>4180</phone_ext>
    <email>marie-helene.lavergne.hsj@ssss.gouv.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle Boisvert</last_name>
    <phone>(514)-345-4931</phone>
    <phone_ext>3200</phone_ext>
    <email>isabelle.boisvert@recherche-ste-justine.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gordon Sussman Clinical Research</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3B 3S6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anastasia Rubanovich</last_name>
      <email>arubanovich@sussmanresearch.com</email>
    </contact>
    <investigator>
      <last_name>Gordon Sussman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sam Wong, MSc, RD</last_name>
      <email>sam.wong@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Julia Upton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Eiwegger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Montréal (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 1P1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Boisvert</last_name>
      <phone>514-345-4931</phone>
      <phone_ext>3200</phone_ext>
      <email>isabelle.boisvert@recherche-ste-justine.qc.ca</email>
    </contact>
    <investigator>
      <last_name>François Graham, MD, M.Sc.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Sainte-Justine</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Pier Roy, RN</last_name>
      <phone>514-345-4931</phone>
      <phone_ext>4201</phone_ext>
      <email>marie-pier.roy@recherche-ste-justine.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Philippe Bégin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CHUS)</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Côté-Bigras, M.Sc.</last_name>
      <phone>819 346-1110</phone>
      <phone_ext>13315</phone_ext>
      <email>sarah.cote-bigras.ciussse-chus@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Alexandra Langlois, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>St. Justine's Hospital</investigator_affiliation>
    <investigator_full_name>Philippe Bégin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>multi-food OIT</keyword>
  <keyword>oral immunotherapy</keyword>
  <keyword>omalizumab</keyword>
  <keyword>symptom-driven protocol</keyword>
  <keyword>double-Blind, randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

